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Abstract
For persons living with HIV, hepatitis C is a major public health problem that must be controlled and could be
eliminated. The challenge arises because the hepatitis C virus (HCV) is prevalent among HIV-infected persons in
most parts of the world, because HIV worsens all HCV outcomes, and because HCV may add additional individual
economic and psychosocial complications to HIV disease. Despite the major benefits of antiretroviral therapy on
HIV outcomes, antiretroviral therapy is not sufficient to halt the complications of HCV. Nonetheless, HCV can be
controlled at all stages, including prevention of infection and cure. Thus, HCV is an eradicable disease. There are
significant inequalities worldwide in HCV control that could markedly constrain the impact of these measures.
Review
Public health importance
HCV coinfection is common
Many persons living with HIV (PLHIV) are coinfected
with the hepatitis C virus (HCV). In Europe, the United
States and Australia, approximately one-quarter of
PLHIV are coinfected with HCV. But these averages
mask marked differences in HCV prevalence based on
the route through which HIV was acquired. By far,
HCV coinfection rates are highest among persons who
have acquired HIV from injection drug use (Figure 1).
Rockstroh and coworkers reported in the large Euro-
SIDA cohort that 1519 (92%) of HIV-infected persons
with a history of injecting drug use were also HCV
exposed [1]. In one study from Russia, 91% of HIV-
infected injecting drug users (IDUs) had HCV antibodies
[2]. Similarly high HIV/HCV coinfection prevalence
rates have been reported from the USA and Australia
[3,4].
In Asia also, nearly all HIV-infected IDUs also has
HCV. For example, in IDUs from Chennai, India, the
prevalence of coinfection with anti-HCV was 86% [5].
Among IDUs in northern Vietnam, almost all (98.5%)
HIV-infected IDUs were also co-infected with HCV [6].
Likewise, HCV infection has been reported in more
than 90% of IDUs in some regions in southern China
[7,8]. Given the linkage with illicit drug use, HCV is also
a special problem for PLHIV in prisons [9]. In addition
to risk-prone illicit drug use, unsafe tattooing contri-
butes to HCV infection in prisons [10].
In contrast to IDUs, HCV coinfection occurs in less
than 15% of persons who acquired HIV from sexual
intercourse [1,11]. One important caveat is the recent
series of HCV outbreaks among HIV-infected men who
have sex with men (MSM) [12,13]. For example, Danta
and coworkers described 111 acute HCV infections
among MSM in England that were associated with high-
risk sexual practices, as well as non-injection use of illi-
cit drugs [12]. It is now clear that this is a widespread
international trend [14].
Basis for HIV/HCV coinfection
There are biologic, sociologic and historic reasons that
HCV coinfection is common in HIV-infected IDUs. Stu-
dies following a single needlestick exposure show that
HCV is approximately a log10 more transmissible than
HIV (1/100 versus <1/1000) [15]. With transfusion of
large blood volumes, such as occurred in haemophilia
populations in the early 1980s, these differences in
transmissibility were inconsequential. Nearly all who
were exposed by transfusion became infected [16].
However, transmission of infectious diseases by drug
use typically involves inocula that are 4-5 log10 smaller.
The average HIV plasma viral load is approximately a
log10 less than HCV [17,18]. Thus, with the very small
inocula that are typically involved in injection drug use,
it is likely that the number of infectious virions in blood
is a major factor in the greater transmission of HCV
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virion is less transmissible or less environmentally stable
than HCV. Ultimately, the net percutaneous transmissi-
bility of small blood inocula is lower for HIV than for
HCV and a major reason for the greater HCV incidence
and prevalence among IDUs (Figure 2).
Less is known about the basis for the sometimes con-
tradictory evidence regarding sexual transmission of
HCV. For example, there are higher than expected HCV
prevalence rates in populations with high-risk sexual
practices, including MSM, but there is very low HCV
incidence between discordant couples and in some
MSM populations. It is possible that, like HIV, HCV is
more transmissible just after acute infection, before for-
mation of neutralizing antibodies and when viral titers
are higher.
However, while this feature might explain low/no sex-
ual transmission from persons with chronic hepatitis C
and relatively more transmission in settings where mul-
tiple exposures to acute infections occur, there is no evi-
dence to support the conjecture. One explanation for
the recent rise in transmission among MSM is that anti-
retroviral therapy has reduced the fear of HIV, resulting
in higher risk sexual practices than when HIV was uni-
formly fatal. Increased use of illicit drugs by injection or
non-injection routes may also contribute. In addition, it
is also possible that there is simply a greater reservoir of
HCV infection among MSM than in prior years, increas-
ing the likelihood of exposure.
Historically, the population reservoir of HCV also
antedated HIV. HCV prevalence markedly expanded
during the mid1900s and is strongly correlated with
stepped-up production of syringes and their worldwide
use both for conventional and illicit drugs [19-21]. This
trend allowed HCV to spread throughout the world and
explains the five- to 20-fold increased HCV prevalence
rates in certain regions where unsafe injections were
widespread, and among IDUs [21]. There is a tendency
of older IDUs to initiate new users by inoculating them-
selves first. Since older IDUs are often HCV infected,
Figure 1 HCV co-infection is common among HIV-infected injecting drug users.
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Figure 2 Incidence of HIV and HCV among Baltimore IDUs.
Adapted from Villano et al [46].
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among IDUs [22]. HIV infection has overspread IDU
populations more recently than HCV which was distrib-
uted decades earlier.
In Baltimore, the HIV prevalence in various risk
groups was extremely low in 1980 and rose sharply in
the early 1990s [23,24]. Consequently, most HIV/HCV-
coinfected IDUs acquired HCV years before HIV, and
for every one HIV/HCV-coinfected IDU, there are
usually two others infected with HCV but not HIV. In
Asia, HIV incidence and prevalence rates first rose in
the mid and late 1980s, especially among IDUs. While
there are certainly individual instances in which HIV
infection occurred first, in most populations in which
injection drug use antedated the introduction of HIV,
IDUs were already infected with HCV. Since HIV infects
activated T cells, the immunologic control of an infec-
tious disease like HCV may differ if it first occurs after
a person is HIV infected, and that consideration may
explain differences in HCV natural history and serore-
version rates in various studies.
HIV infection complicates the course of hepatitis C
Although the mechanism is really not well understood,
HCV infection has a well-characterized course that is
a d v e r s e l ya f f e c t e da te v e r ys t a g eb yH I V( F i g u r e3 ) .
Although 30% to 40% of persons spontaneously clear
HCV infection, the chances of spontaneous resolution
are at least two-fold lower in HIV/HCV-coinfected per-
s o n s[ 2 5 ] .T h o s ew h od od e v e l o pc h r o n i ch e p a t i t i sC
have higher HCV viral loads if they are coinfected with
HIV than those with just HCV [26].
Likewise, persons chronically infected with the same
HCV genotype are about half as likely to respond to the
same dose and duration of peginterferon and ribavirin
therapy if they are HIV coinfected compared with those
with just HCV [27,28]. HIV/HCV-coinfected persons are
also twice as likely to develop cirrhosis over a shorter per-
iod of time [29]. Clinical manifestations of liver failure,
such as ascites, encephalopathy and esophageal varices, all
occur more often in HIV/HCV-coinfected persons [30].
Antiretroviral therapy is not sufficient to negate the effects
of HIV on the course of hepatitis C
Antiretroviral therapy is probably the most important
biomedical breakthrough in the past two decades. Rates
of HIV-related opportunistic infection and related mor-
tality have sharply dropped since adoption of antiretro-
viral therapy in the mid 1990s. Antiretroviral therapy
also worked in sub-Saharan Africa and wherever there
was a public health system to deliver it. Transmission of
HIV to infants is also dramatically reduced in settings
where antiretroviral therapy is given. Even the relatively
hard-to-tolerate first-generation antiretroviral therapy
reduced mortality.
The enormous effectiveness of antiretroviral therapy
and the observation that HIV makes liver disease worse
raises the question of whether antiretroviral therapy
eliminates or at least attenuates the effect. This is an
intense area of investigation with too much data on
both sides of the question to review here. What is clear
is that antiretroviral therapy i sn o ts u f f i c i e n tt oprevent
complications of HCV, antiretroviral therapy does not
affect the rate of HCV persistence, and it does not
diminish the HCV viral load (in some persons, antiretro-
viral therapy actually increases the HCV-RNA level by a
small amount) [31].
Antiretroviral therapy might improve the response to
interferon and ribavirin, but this hypothesis has never
been appropriately tested, and, since the majority of
published data on peginterferon/ribavirin response in
HIV/HCV-coinfected persons are on persons taking
fully suppressive antiretroviral therapy, it is clear that
“normal” responses are not restored. Likewise, rapid
progression of liver fibrosis has been described even in
persons taking fully suppressive antiretroviral therapy,
making it clear that antiretroviral therapy is not suffi-
cient to control HCV infection in PLHIV.
While the lifespan of HIV-infected persons taking
antiretroviral therapy has been prolonged, the lives of
those coinfected with HCV remain much shorter. In
one study from Denmark, mortality rates from the age
of 25 years were compared in 3990 HIV-infected per-
sons with the general population, and survival curves
were fitted [32]. Mortality dropped from a high of 124/
1000 person years (PYs) in the pre-antiretroviral therapy
period to 38/1000 PYs in 1997-1999 to 25/1000 PYs in
2000-2005. However, the impact was markedly different
by HCV coinfection status, with mortality rates in 2000-
2005 of 57/1000 PYs among the HCV coinfected com-
pared with 19/1000 among those without known HCV
infection (Figure 4).
Treatment 
Liver failure or cancer 
Infection 
Recovery Persistence 
Viral load
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Effect of:
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Figure 3 HIV infection adversely affects all stages of hepatitis C.
Thomas et al. Journal of the International AIDS Society 2011, 14:22
http://www.jiasociety.org/content/14/1/22
Page 3 of 8By removing the HCV-coinfected persons, survival of
HIV-infected persons on antiretroviral therapy was
expected to approach that of the general population,
38.9 versus 51.1 years. Some of this is caused by other
health problems, like overdose or accidents. However,
liver disease is now the second leading cause of death
among persons with HIV taking antiretroviral therapy
[33,34]. Given the systematic underreporting of liver dis-
ease, the true impact is likely greater.
Beyond statistics
There are consequences of HCV infection that are often
not appreciated by physicians and public health officials.
Since HCV often comes from injecting drug use,
ongoing infection can be an indelible scar of a difficult
phase of life. Having overcome dependency and other
related challenges and having achieved an undetectable
HIV-RNA on antiretroviral therapy, HCV can represent
a major residual concern for PLHIV.
There may also be stigma associated with being HCV
infected [35]. In some societies, this can be extremely
severe. For those who have been undergoing HIV treat-
ment, or have been in search of appropriate HIV drug
combinations, the addition of an HCV regimen can be
discouraging. Often already having undergone a battle
with the HIV medications, coinfected persons may not
emotionally or psychologically embrace the addition of
highly toxic drugs to already complex treatment plans
[36]. Patients have various levels of tolerance, which
together with the different side-effect experiences, may
produce an array of responses from little perceivable
impact on daily functions to major suffering and out-
right non-compliance. The majority of patients, of
course, fall somewhere in between, and none enjoy
HCV treatment.
Once diagnosed with HCV, IDUs who historically
associate needle use with illicit drug use, now must
inject themselves with a compound that often exacer-
bates depression [27]. For newly recovering addicts, this
process, along with the HCV diagnosis, can be detri-
mental to their efforts to maintain abstinence from
mood-altering drugs, and, therefore, they may even
refuse to participate, become non-compliant, or return
to illicit drug use. For some of the co-infected persons,
especially young HIV-positive persons, not responding
to treatment constitutes a failure of modern medicine to
meet their health needs. This realization may produce
all types of psychological responses, like self-blame,
severe depression or misplaced rage.
Control of HCV infection
Proof-of-principle studies have demonstrated that all
phases of control are possible, from prevention to treat-
ment. At the same time, most research suggests that
HCV control will create huge disparities in outcomes.
Figure 4 Markedly lower survival for HIV/HCV-coinfected persons in Denmark: 2000-2005. Reproduced from Lohse et al [32].
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HCV transmission can clearly be prevented. Transfusion
transmission of HCV has virtually been eliminated in any
setting where donations are screened for HCV antibodies
and RNA [37]. Likewise, nosocomial transmission has
been reduced by observance of blood-borne precautions.
Prevention of HCV transmission among IDUs can be
achieved but is more difficult than HIV
Harm-reduction efforts, such as needle exchange, have
been associated with reductions in HIV and HCV inci-
dences in some settings. In Baltimore, HIV incidence
rates among IDUs have dropped markedly from ~5 per
100 person years in 1990 to nearly zero since 2000. In
the same Baltimore cohort, HCV incidence dropped
from 22 to eight per 100 person years over the same
time span (Mehta S, personal communication).
Given the greater transmissibility of HCV and the
greater reservoir of IDUs already infected (as we have
discussed), it is not surprising that even stronger harm-
reduction measures will be needed to eliminate new
HCV infections. If HCV is a log10 more transmissible
than HIV, public health interventions may need to be
an order of magnitude stronger to control HCV.
Control of chronic hepatitis C
HCV infection can also be controlled even after it
occurs. The first step in controlling chronic hepatitis C
is detecting infection by screening and testing. Nearly all
guidelines indicate that HIV-infected persons and all
IDUs be tested for HCV [38-40]. However, the effective-
ness of such guidelines and the associated practices var-
ies markedly.
In the USA, rates of testing and awareness are lower.
Some have estimated that 70% of all those with chronic
hepatitis C in the USA are unaware of their infection.
Data from The TREAT Asia (Therapeutic Research,
Education and AIDS Training in Asia) HIV Observa-
tional Database, a collaborative observational cohort
study involving 15 participating sites in 12 cities in the
Asia and Pacific region, indicate that hepatitis testing
data are available in nearly half of the TAHOD patients,
with prevalence of HBV and HCV coinfection each at
approximately 10% [41]. Lack of access to HCV testing
and counseling is a major problem throughout eastern
and central Europe and in Asia. The cost of the test is a
major barrier.
Stigmatization of illicit drug use and HCV infection
itself are obstacles to screening programmes. However,
these issues have been addressed for HIV and can be
overcome by a variety of measures that are likely to dif-
fer in various cultures.
Opting for HCV testing
The prevalence of HCV infection is sufficiently high
to justify testing of any IDU and the stigma of
acknowledging illicit drug use is sufficiently high that
routing testing may be preferable to screening for specific
HCV risk factors (and then testing those with risk). HCV
testing should include counseling and, ideally, opportu-
nities for disease management, which sometimes will
involve treatment.
Given the small proportions of HCV-infected persons
who are currently aware of their infections, greater
effort also should be given to development and imple-
mentation of rapid HCV tests. For example, tests that
can be used at any venue and provide results that can
b ei n t e r p r e t e da tt h es a m ev i s i ta r eh i g h l yd e s i r a b l e ,a s
with HIV [42]. Counseling to reduce transmission to
others and to reduce the harm of alcohol use is essen-
tial. Vaccination should be provided to susceptible per-
sons to prevent hepatitis A virus and hepatitis B virus
infections [39,40].
Treatment is the most potent form of controlling chronic
hepatitis C
HCV infection can be cured. Even in persons with HIV,
suppression of replication during treatment and for six
months after treatment (called a sustained virologic
response, or SVR) is considered a cure because more
than 98% will remain free of HCV viremia off medica-
tion for five or more years [43]. In addition, end-stage
liver disease, liver cancer and other complications of
HCV infection are reduced [44].
The global standard of care is peginterferon alfa and
ribavirin, a combination that is expensive, toxic and
effective approximately 50% of the time. Thus, guide-
lines currently recommend that treatment be used only
for persons most likely to benefit (high disease stage,
low risk of adverse events). However, treatment
improvements are coming rapidly. “Highly active” HCV
therapies are being developed, and approval of new
compounds (often called direct acting agents, or DAAs)
is expected in 2011. It is already clear that DAAs
improve cure rates and will probably also reduce treat-
ment durations [45]. In addition, clinical trials of inter-
feron-free treatments are already in phase 2. Thus, it is
reasonable to anticipate a day when 90% of HCV-
infected persons could be cured by 24 weeks or less of
treatment.
Even elimination of HCV is possible
There are many reasons why HCV could (and should)
be eliminated. Humans are the only reservoir of HCV
infection. Unlike HIV or HBV, there is no latent reser-
voir of HCV. When a patient is cured, they are no
longer infectious to others. If environmental reservoir is
reduced enough, infection will not be sustained. It is
simply a matter of better drugs, which are anticipated,
and then the allocation of resources to treat a sufficient
number to break the transmission chain.
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It is likely that existing inequities in HCV outcomes will
expand markedly as therapies improve. Discrepancies
already exist in the prevention and treatment of HCV
infections worldwide. HCV transmission by transfusion
has been eliminated from the USA and Europe, but con-
tinues in areas in the world in which donations are not
screened effectively. HCV infection can be diagnosed,
but fewer than 10% of the 170 million persons with
HCV worldwide are aware of their infections. Even
fewer have the opportunity for treatment.
In an interview with the United Nations Office on
Drugs and Crime, Loon Gangte, President of the Dehli
Network of Positive People, observed that the price of
peginterferon and ribavirin exceeds the lifetime income
of most Indians http://www.unodc.org/india/interview-
with-mr.-loon-gangte.html.
Conclusions
In this way, HCV is much like HIV in the mid 1990s.
HCV is about to enter an exciting era of more potent
treatment that will reduce the mortality and morbidity
associated with the infection. Treatments will continue
to improve as newer generations of medications are
developed. Like HIV, the benefits of treatment will be
narrow unless there is a global response, such as what
has occurred to bring antiretroviral therapy to millions
of additional persons worldwide.
Will there be a Global Fund or PEPFAR for HCV?
Even if all those who take HCV treatment are cured, if
fewer than 10% receive care, the global impact of treat-
ment remains minimal (Figure 5). The effectiveness of
efficacious therapy will be low.
On 21 May 2010, the World Health Assembly passed
a resolution that called for the World Health Organiza-
tion to observe World Hepatitis Day on July 28 and to
develop a comprehensive approach to control of chronic
hepatitis. This is an exciting first step. However, a tre-
mendous amount of work still needs to be done to
bring new HCV treatments to those who need them
and, perhaps some day, to eradicate another global
infectious disease.
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Figure 5 The disparity between potential HCV treatment efficacy and projected HCV treatment effectiveness. Adapted from Thomas DL [47].
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